Drug Profile


Alternative Names: PhotoPoint SnET2; Photrex; Purlytin; REM-001; REM-001 Therapy; Rostaporfin-PDT; Sn(IV) etiopurpurin; SnET2; SnET2-PDT; Tin ethyl etiopurpurin

Latest Information Update: 07 Jan 2017

Price : $50

At a glance

  • Originator
  • Developer Adgero Biopharmaceuticals; Miravant Medical Technologies
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Lipid peroxidation stimulants; Photosensitisers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Breast cancer
  • Phase I/II Basal cell cancer
  • No development reported Age-related macular degeneration; Psoriasis
  • Discontinued Benign prostatic hyperplasia; Brain cancer; Coronary artery restenosis; Diabetic retinopathy; Glaucoma; Head and neck cancer; Kaposi's sarcoma; Lung cancer; Prostate cancer; Skin cancer

Most Recent Events

  • 05 Jan 2017 Phase-I/II clinical trials in Basal cell cancer (Recurrent) in USA (IV)
  • 05 Jan 2016 Phase-III clinical trials in Breast cancer (Metastatic disease, Second-line therapy or greater) in USA (IV) before January 2016
  • 05 Jan 2016 Adgero Biopharmaceuticals plans to file for orphan drug and breakthrough therapy designations for Rostaporfin to US FDA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top